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ALTERATION OF GALLIUM BIODISTRIBUTION
‘ ' USING INDIUM COMPLEXES FOR ENHANCED

EARLY IMAGING

gallium will decrease blood activity without signi?
cantly reducing tumor activity (J Nucl Med 20: 656,

BACKGROUND OF THE INVENTION

1979; Invest Radiol 14: 482-492, 1979).
Several investigators have used the second approach,

1. Field of the Invention '

The present invention relates to a diagnostic nuclear
medicine. More speci?cally, the present invention re
lates to tumor imaging utilizing radioactive gallium. '

employing a chelating agent, desferoxamine, to reduce

gallium blood activity (J Nucl Med 21: 421-425, 1980; J
Nucl Med 20: 248-251, 1979; Radiology 131: 775-779,

2. Description of the Prior Art

1979; Radiolog 130: 241-244, 1979). The resulting gal

Gallium-67, as the carrier-free citrate,-is used rou

lium desferoxamine complex is eliminated via the kid

tinely in clinical medicine in the diagnosis, staging and
monitoring of several neoplastic disease states (Semin
Nucl Med 6: 331-334, 1976). Unfortunately, this agent is
plagued with imaging problems which are related to

ney at a rate greater than that observed for gallium

alone. Unfortunately, this clearing agent must be admin
istered 24 hours after the gallium injection in order to
minimize loss of tumor activity.

plasma protein binding. Speci?cally, gallium ‘has an
affinity for blood and soft tissue proteins, and when
given in very low doses, is extensively bound (J Phar
macol Exp I71erapeut 168: 193-198, 1973). Gallium also
has an affinity for tumors (Science 167:289-290, 1970; J
Nucl Med 10: 103-105, 1969) and abscesses (J Nucl Med

SUMMARY OF THE INVENTION
It is, therefore, a primary object of the present inven

tion to provide improved radiopharmaceutical compo
sitions and methods for tumor imaging which overcome
or reduce the above mentioned problems of the prior

21: 484-488, 1980). After intravenous administration, '

gallium activity in tumors is seen immediately and
reaches a maximum within eighteen hours (Semin Nucl 25

Med 8: 193-203, 1978). Biologic clearing of gallium
from blood and soft tissue binding sites is a slow pro
cess, and results in the presence of image obscuring

activity long after the ideal imaging time. Three major
consequences of this binding phenomenon are: (a) it is

necessary to delay imaging procedures for long periods
of time (48-72 hours) to allow for the clearance of non

productive radioactivity; (b) the long waiting period
allows the build-up of image obscuring activity in the
intestinal tract due to secretion of gallium into the large
bowel (J Nucl Med 14: 208-214, 1973); and (0) pro
longed retention of large quantities of 676a in the body
results in a relatively high radiation dose (J Nucl Med

.

application due to the large dose of iron required (J
Nucl Med 21: 421-424, 1980). More recently, it has been
shown that relatively large doses of non-radioactive

art.

Carrier-free solutions of gallium-67 citrate were ad
ministered to normal and tumored rats, and blood levels
of radioactivity were monitored as a function of time.

Metal complexes of aluminum, gallium, indium or thal
lium were administered at times varying from two to six

hours following the injection of the radiopharmaceuti
cal. In the cases of indium and gallium, the blood activ
ity was observed to decrease very rapidly, and a gener

alized clearing of soft tissue activity was observed. Sim
ilar studies using imaging techniques, reveal that activ
ity bound within tumors is obviously affected by the
addition of moderate doses of carrier gallium. When
indium citrate was administered two hours after the

radiopharmaceutical the tumor activity increased sig

ni?cantly. When carrier-free gallium-67 was adminis
Several reports have described methods or agents 40 tered simultaneously with indium citrate, the biodistri
bution of gallium in rats bearing transplanted tumors
which attempt to enhance the process of imaging a
(lymphoma and hepatoma) was found to be dramati
tumor or abscess by shortening the biologic half life of
cally altered. Two hours after dosing, radioactivity is
carrier-free gallium-67 citrate. Generally, these fall into
observed in the kidney, bladder, bone and tumor. Other
two categories: (a) agents which compete with radioac
tive gallium for blood and tissue binding sites, thus 45 areas and tissues were essentially void of activity. This
releasing the radioactive metal ion making it available
rapid clearance of non-productive gallium from diffmse
for kidney elimination; ‘or (b) complexing‘or chelating ‘ soft tissues, blood and organs such as liver, lung and
agents which compete with blood and tissue binding
spleen demonstrates the potential for use of the gallium
sites for free gallium, forming a complex which is rap
68 coupled with emission tomography.
idly cleared by the kidney.
Therefore, in accordance with the present invention,
50

12: 755-756, 1973).

The initial work took the ?rst approach and used a
group (IIB) metal complex (Scandium citrate) as a se

lective competitive binding agent (South Med J 66:
1339-1340, 1973; JNucI Med 21: 361-365, 1980). Scan
dium, by occupying gallium binding sites on blood pro
teins, prevents the accumulation of gallium on'these
sites. Scandium appears to have little or no effect upon

it has been discovered that intravenous injection or’ a

non-radioactive indium complex simultaneously with,
shortly before or shortly after, the intravenous injection
of carrier free gal1ium-67(67Ga) or gallium-68(68G:e),
alters the biodistribution of the radioactive gallium.
More speci?cally, the indium complex occupies ncm
tumor gallium receptor sites, and, therefore, the gallium

gallium binding in tumors. When used in animal studies,
will not be retained on these receptor sites to thereby
where gallium-67 and scandium citrates were injected
obscure the imaging process. In other words, the an
simultaneously, extremely high tumor to blood and 60 dium complex has a high affinity for non-tumor galliuun
tumor to tissue ratios were obtained. Unfortunately,
scandium produces a severe hemolytic anemia when
administered to man (South Med J 66: 1339-1340, 1973;
J Nucl Med 21: 361-365, 1980). The use of iron dextran
in similar fashion to clear gallium from rabbits bearing 65

induced abscesses resulted in the clearing of gallium
with enhanced abscess uptake of gallium (J Nucl Med
17: 356-358, 1976). This ion, however, has no clinical

receptor sites leaving the gallium free to be bound to tine

tumor gallium receptor sites.
It has been shown that indium complexes alter gailii
um-67 biodistribution in rats bearing transplanted tu

mors (lymphoma and hepatoma).
The indium and gallium complexes may be adminns

tered by injection, with intravenous injection beirng
preferred. The gallium complexes must be administered

4,448,763

3

ih'carrier-free form with doses in the range of about 0.25
to 500 ng being preferred. In humans, doses up to 3 mg

4

FIG. 2 is a rectilinear scan of a normal Sprague Daw

ley rat before and after a clearing dose (3.3 rug/Kg) of
non-radioactive gallium citrate was administered six

maybe employed. The indium complexes may be ad
ministered in doses of from about 0.1 to 0.7 mg with

hours post radiopharmaceutical dosing.

doses of from about 0.1 to 0.3 mg being preferred. In
humans doses will be based on blood protein content,

FIGS. 3A-3C are scans (Union Carbide Cleon model

720 large ?eld gamma camera) of Buffalo rats bearing

and may vary up to 50 mg.
All water-soluble forms of indium such as water-solu'
ble salts may be used. These water soluble forms include

implanted 5123C hepatomas.
FIG. 3A shows the rats two hours'after radiopharma- '
ceutical dosing. At this point, the rat on the left re

water-soluble organic salts, water-soluble inorganic

ceived carrier gallium citrate (3.3 mg/Kg) and the rat
on the right received indium citrate (2.1 mg/Kg).
FIG. 3B shows the rats three hours after radiophar
maceutical dosing and one hour after injection of the

salts as well as various water-soluble complexes. Exam

ples of water-soluble organic salts include indium ci
trate, indium lactate, indium tartrate, indium phytate,
and indium phthallate. Examples of water-soluble inor
clearing agent.
ganic salts are indium chloride, indium nitrate, indium
FIG. 3C shows the rats ?ve hours past radiopharma
sulfate, and indium bromide. Another useful form of _ ceutical dosing and three hours after the clearing dose.

indium is an indiumtransferrin complex.
All water-soluble forms of gallium suchas water-sol
uble salts are also useful. Examples of water-soluble

FIGS. 4A-4E are scans (Union Carbide Cleon model

forms include water-soluble organic salts, water-soluble 20
inorganic salts as well as various water-soluble com

plexes. Examples of water-soluble organic salts include

FIG. 4A is cumulative over the time period 0 to 10

gallium citrate, gallium lactate, gallium tartrate, gallium
phytate and gallium phythallate. Examples of water-sol
uble inorganic salts include gallium chloride, gallium
nitrate, gallium sulfate and ‘gallium bromide. An exam
ple of another form of gallium is a complex of gallium
and transferrin.

720 large ?eld gamma camera) of Buffalo rats, bearing
Morris 5123C hepatoma is injected with a single solu
tion containing carrier-free gallium-67 citrate and 2.1
mg/Kg indium citrate.
mm.

25

FIG. 4B is the time period from 10 to 20 min.
FIG. 4C is the time period from 20 to 30 min.
FIG. 4D represents the same time period taken one
hour after the injection.
FIG. 4E represents the same time period taken two

Radiopharmaceutical compositions may be prepared
hours after the injection.
by dissolving the gallium and/or indium complex in any 30
EXAMPLES;
acceptable solvent such as water, normal saline, buffer
normal to the pharmaceutical preparation, and mixtures
In this study, an external blood-loop technique (IntJ
thereof. Normal saline is preferred as a solvent.
ofAppl Radiat [sot 29: 189-190, 1978) is used to monitor
It is preferred to administer the gallium and the in

. blood activity of the radiopharmaceutical as a function

dium simultaneously, however, the indium may be ad 35 of time. Relative tissue concentrations are monitored by
ministered before or after the gallium, preferably within
external imaging.

2 hours before or after the gallium.

'

CHEMICALS AND

When gallium and indium are administered in accor

dance with the present invention the following advan
tages are realized: the time required for image obscuring
blood and/or soft tissue radioactivity to clear the body,
enabling one to obtain a clear image of the tumor, is

RADIOPHARMACEUTICALS
All agents, both radioactive and non-radioactive,
were used as purchased; without further puri?cation.
Gallium-67 citrate was obtained from Medi-Physics

reduced; the radiation dose to the patient is reduced by
(Neosean ®); thallium triacetate and indium chloride
increasing the rate at which the radioactive gallium
were obtained from Johnson-Mathey Chemicals Lim
clears the body; and the short-lived position emitting 45 ited as the nonohydrate; and aluminum lactate was ob
gallium-68 isotope may be recorded by emission tomo
tained from I.C.N. Pharmaceuticals.

graphic imaging equipment to thereby allow viewing of
the tumor in three dimensions. The radioactive gallium
may be measured by using external scintigraphic tech

niques (either photon or positron).
BRIEF DESCRIPTION OF THE DRAWINGS

Other objects and advantages of the present invention
will become apparent from a study of the following

non-limiting examples and drawings in which
FIGS. lA-lD are distribution pro?les for carrier~

free gallium-67 citrate:
FIG. 1A is a typical pro?le with no clearing agent

added;
FIG. 1B is a typical pro?le observed when carrier

gallium citrate (3.3 mg/Kg) is given 6 hours (360 min)

after radiopharmaceutical dosing;

FIG. 1C is a typical pro?le observed when indium

chloride (2.1 mg/Kg) is given 6 hours (360 min) after

radiopharmaceutical dosing; and

l
l

l

3822-3823, 1950. Gallium nitrate (375 mg) was dis
50 solved in a minimum volume of boiling concentrated

hydrochloric acid, citric acid solution (20% w/v, 2.5
ml) was added thereto, the resulting solution cooled to
room temperature and neutralized with sodium hydrox
ide solution (?nal concentration: Ga 15 mg/ml-ZO mg
citrate/ml, pH 7.4). In a similar manner, indium citrate
was prepared (?nal concentration: In 6.67 mg/ml-ZO mg

citrate/ml). Aqueous solutions of aluminum lactate
(1.42 mg/ml) were obtained by solution in normal sa

line. All solutions were ?ltered (0.22u millipore ?lter)
prior to use.

ANIMAL PREPARATION AND
RADIOPHARMACEUTICAL DOSING
For blood clearance studies, male Sprague Dawley
65 rats weighing 250—300 grams were used. The animals

FIG. 1D is a typical pro?le observed when indium

were anesthetized by peritoneal injection of an aqueous

citratc (2.1 mg/Kg) is given 6 hours (360 min) after

solution of urethan (l gm/Kg). The right carotid artery

radiopharmaceutical dosing.

1

Gallium citratesolutions were prepared by a method
similar to that disclosed in J Am Chem -Soc 72:

and left jugular vein were exposed and an external

5
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blood loop (PE-50 tubing; volume=0.l4 ml) was in
. serted between the vessels. Blood was diverted from the

artery, through the loop, and back to the animal via the

vein (Int J of Appl Radiat Isot 29: 189-190, 1978). The

TABLE 1
Relative ability of the group (IIIA) metals to clear

676a from blood six hours after injection of the radiophannacemi
cal

right external jugular vein was then exposed and cannu 5 Non
radioactive
lated asan injection site. The animal was placed in a
Metals
lead cradle and the blood loop inserted into the shielded

% Decrease in.
Blood Activity

% Increase in
Blood Activity

Net
Decrease

well of a sodium iodide.thallium crystal. The animal
received an injection of carrier-free gallium citrate

Thallium
Aluminum
Gallium

0
9
40

0
3
15

0
6
25

(100-120 uCi) via the jugular cannula. Blood activity

Indium (Cl)

85

25

60

within the loop was continuously monitored as a func

tion of time using a Packard Model 9012 Multi-channel

Analyzer/Multi-scaler system (Packard Instrument
Co., Downersville, 11].). Six hours post injection, the
animal received a second injection containing one of the

clearing agents (=72 mmole/Kg). In subsequent experi
ments, clearing agents were administered two hours
after or simultaneously with the radioactive dose.
Initial studies used non-tumored male Sprague Daw
ley rats weighing between 250 and 300 grams. Subse
quent studies in tumored rats used male Buffalo rats

There was no change in blood activity following a dose

of 7.2 mmoles/Kg of thallium triacetate. Aluminum
lactate caused a reduction of 9% in blood activity fol
lowed by a 3% rise in activity. The net reduction in
blood activity was only 6%. Indium chloride proved to
be the most potent of the clearing agents tested. As was
the case with non-radioactive gallium, indium chloride

(FIG. 1C) caused a rapid drop in blood activity (85%)
followed by an increase which peaked 1.5 to 2 hours
after the clearing dose was given. The net reduction in
blood activity was 60%. When indium citrate was used

bearing a 5123C hepatoma (The tumor line was initiated ‘ in similar fashion, the blood curve was observed to fall
from donor animals donated by Drs. R. L. Hayes and B. 25 77% and there was no signi?cant rise in blood activity

Byrd of the Oak Ridge Associated Universities). In all .

(FIG. 1D). The distributional difference between in

imaging studies, the animals were anesthetized by intra
peritoneal injection of urethane (l grn/Kg), and the left

dium chloride and indium citrate could be explained if
citrate offered a weak, transient binding for that gallium

which is displaced from the blood protein binding sites
external jugular vein cannulated as a closing site. The
animals were then positioned under the detection of the 30 now occupied by indium. The gallium citrate complex

'y-camera (Union Carbide; CLEON 720 Large Field
Gamma Camera coupled with a CLEON 110 Image

thus formed must be rapidly cleared by the kidney. This
is the same mechanism suggested above for the rapid
drop in blood activity seen at early times. In the absence

Processor) and images were obtained periodically.
Following a single intravenous injection of carrier 35 of citrate, gallium would seek alternate, non—vascular,
binding sites (probably surface proteins in tissues) from
free gallium-67 citrate in the normal Sprague Dawley
which it would undergo a slower redistribution to

rat, prepared as described, a blood activity-time curve
similar to that shown in FIG. 1A is observed. The curve

blood sites vacated as indium undergoes distribution
processes.

is characterized by a rapid distribution phase followed
The two most successful clearing agents, gallium and
by a slower elimination phase. The rapid distribution 40 indium citrate, were furher investigated to determine if
process appears to be complete four to six hours after
varying the length of time between radiopharmaceuti
dosing and is in itself multiplastic. There is a very rapid
cal dosing and clearing agent dosing altered the results.
Gallium (3.3 mg/Kg) cleared 78% of the blood activity
component (t; = 12 seconds) which may be due to kid
when given at two hours after the radiopharmaceutical.
ney elimination of the citrate complex. This process
would become insigni?cant as gallium complexed with 45 This was followed by the characteristic rise in activity
which resulted in a net clearance of 70%. Indium citrate
citrate is transferred to binding sites on blood proteins,
reduced the blood activity by 78% and no subsequent
thus becoming less available for kidney elimination.
rise in activity was observed.
'
The effect of a relatively large dose of non-radioac
Preliminary imaging studies performed in non
tive gallium (3.3 mg/Kg) given six hours after the initial 50 tumored rats injected with one of the four clearing
injection is seen in FIG. 1B. There is a dramatic, rapid
agents six hours post dosing, gave results which gener
drop in blood activity (approximately 40% of the blood
ally paralleled the blood studies. Injections of thallium

activity is removed). This is followed by a rise in blood
activity, possibly due to release of 67Ga from less avail
able gallium stores by an isotopic exchange process.
The rise in blood activity peaks 1.5 to 2 hours after the

blood/soft tissue regions and into the kidneys and the

second injection and subsequent gallium elimination

bladder (FIG. 2).

parallels that observed when no clearing agent is used.
When gallium is administered in this manner, the blood

activity measured eight hours post radiopharmaceutical

or aluminum yielded no signi?cant redistribution of the

radioactivity. Injections of non-radioactive gallium or
indium citrate shifted the radioactivity out of the
Clearing studies were performed on tumored rats

using these agents in dosages suggested as optimal in
both blood and preliminary imaging studies. Indium

citrate was dosed at the level of 2.1 mg/Kg, and gallium
dosing, is approximately 25% less than that observed
citrate was dosed at 3 mg/Kg and 15 mg/Kg. “'hen
when no clearing agent is given.
given six hours after the initial injection, the high dose
In similar experiments, equimolar quantities of non
of non-radioactive gallium resulted in obvious redistri
radioactive aluminum, indium, or thallium complexes 65 butions of radioactivity which would have obscured
were injected six hours after the carrier-free gallium
chest and abdominal images (i.e. liver, spleen, lung and
dose. The results of these studies are summarized in

Table l.

intestine). However, tumor activity was observed to
decrease. The lower dose of gallium generally has a less

4,448,763
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dramatic effect in that a great deal of activity remains in

The invention being thus described, it will be obvious

the ‘abdomen, particularly in those organs with high
reticuloendothelial (RE) activity (liver and spleen).

that the same way be varied in many ways. Such varia
tions are not to__ be regarded as a departure from the

Also, loss of activity from the tumor is much less. In

spirit and scope of the invention, and all such modi?ca

dium is obviously the superior agent, reducing activity

tions as would be obvious to.one skilled in the art are
intended to be included within the scope of the follow

within the RE rich tissues while not depleting tumor
activity. However, the effect is not dramatic enough to
indicate clinical signi?cance.
When the clearing agent was given two hours post

ing claims. .

What is claimed is:

1. A radiopharmaceutical composition, comprising:

radiopharmaceutical dosing, there were signi?cant
changes in gallium-67 distribution (FIG. 3). Gallium

radioactive gallium, non-radioactive indium and a
pharmaceutically acceptable carrier or diluent.

citrate (3 mg/Kg) causes some clearing in the upper
abdomen and in regions of the lower abdomen. There
was little loss of activity from the tumor region and the

2. A radiopharmaceutical composition according to
claim 1, wherein said radioactive: gallium is gallium 67
or gallium 68.

diagnostic potential of the image was improved. The

3. A radiopharmaceutical composition according to

results from use of indium citrate were somewhat more

claim 1', in the form of an injectable solution.

dramatic in that the activity is greatly diminished
4. A radiopharmaceutical composition according to
throughout the soft tissue regions. Activity in the liver
claim 3, wherein said gallium and indium are present in
spleen-lung region is greatly reduced as it is in the lower
of water-soluble salts or complexes.
abdomen. The most signi?cant distributional change, 20 the5.form
A
radiopharmaceutical
composition according to
however, is the obvious ingrease intumocaetivityf'rhis
claim
4,
wherein
the
concentration
of said indium in
suggests that themecliatiams by which’i‘giallium local
said injectable solution is between 0.3 mg/ml and 2.1
izes in tumorfrT-Est differ from that directing its localiza
mg/ml.
tion iii other tissues and blood. Further, this suggests
6. A radiopharmaceutical composition according to
‘ that indium, like scandium, may allow tumor localiza 25
claim
5, wherein the said gallium in said injectable solu
tion of activity while preventing the accumulation of
tion is in carrier-free form.
activity in blood and tissue when given simultaneously
v7. A radiopharmaceutical diagnostic kit, comprising:
with the radiopharmaceutical. To test this hypothesis,
an effective tumor imaging amount of water-soluble

indium citrate was given with gallium-67 citrate as a

single solution. As shown in FIG. 4, the distributional 30

pattern of gallium-67 is drastically altered. Twenty
minutes after the mixed dose is given, there is little
activity outside the kidneys, bladder, tumor and bone.
After two hours, there is essentially no activity in the
animal other than in the above mentioned regions.
35

Indium citrate, has the ability to successfully compete
with gallium for blood and soft tissue binding sites, yet
it does not compete for gallium binding sites in tumor.

radioactive gallium; and

'

an effective tumor imaging improving amount of
water-soluble non-radioactive indium.
8. A method for detecting tumors in mammals com
prising:

'

administering to said mammals an effective tumor
imaging amount of radioactive gallium and an ef
fective tumor imaging improving amount of non

radioactive indium and measuring the biodistribu
tion of said radioactive gallium using external scin

This is a property shared with scandium and iron. It is

tigraphic techniques.

potentially a clinically signi?cant ?nding in that galli

9. A method according to claim 8, wherein said gal
um-67 citrate, under the distributional in?uence of this
lium is administered by injection.
type agent could be useful for general metastatic
10. A method according to claim 9, wherein said
searches. No longer would the liver-spleen region, a
indium is injected in an amount of between 0.1 mg/Kg
common metastatic site, be obscured by activity taken
up by the RE system. Further, because of the reduced 45 and 2.] mg/Kg.
11. A method according to claim 9, wherein said
time between dosing and imaging, signi?cant abdominal

gallium is injected in carrier-free quantities.
12. A radiopharmaceutical composition according to

secretion does not occur, thus the gut area is free-of

activity.

claim 1, wherein said composition includes a water-sol

Unlike scandium, indium is not known to rupture red

uble organic salt of radioactive gallium.
13. A radiopharmaceutical composition according to

blood cells. Toxicity studies following single doses of
indium citrate indicate that the doses used in this study
for clearing gallium are in the toxic range (Proc Soc Exp

claim 1, wherein said composition includes a water-sol
uble organic salt of non-radioactive indium.

Biol Med 29: 1188-1193, 1931; Cancer Chemother Rep
Part 1 59: 599-6l0 1975;.l1ndustHyg Tax 24; 243-254,
1942). However, preliminary blood studies in normal

14. A radiopharmaceutical composition according to
claim 1, wherein said composition includes radioactive

rats suggest that clearing dose of indium citrate can be
reduced by as much as an order of magnitude without

gallium citrate.
15. A radiopharmaceutical composition according to

loss of clearing potential. Indium doses in this range

‘ claim 1, wherein said composition includes non-radioac

were not reported to be toxic.

The use of indium citrate simultaneously with the 60

radiopharmaceutical could shorten the dose-to-image
waiting period from day to minutes, making possible the
use of the shorter lived isotope gallium-68 (t5=68 min
Utes) for tumor imaging. This isotope, while biologi
cally identical to gallium-67, has the added advantage of

tive indium citrate.

16. A pharmaceutical composition according to claim
1, wherein said composition includes a water-soluble

inorganic salt of radioactive gallium.
17. A pharmaceutical composition according to claim

tomggllipily and all the inherent advantages of three

1, wherein said composition includes a water-soluble
inorganic salt of non-radioactive indium.
18. A radiopharmaceutical composition according to
claim 1, wherein said composition includes an organic

dimcnslnll?i imaging.

salt of radioactive gallium selected from the group con

positron emission, introducing the potential for emission

4,448,763

claim 1, wherein said composition includes an inorganic
salt of non-radioactive indium selected from the group
consisting of indium chloride, indium nitrate, indium
sulfate and indium bromide.

_ trate, gallium phytate and gallium phythallatc.

19. A radiopharmaceutical composition according to
claim 1, wherein said composition includes an inorganic
salt of radioactive gallium selected from the group con

23. A radiopharmaccutical composition according to

sisting of gallium chloride, gallium nitrate, gallium sul

claim 1, wherein said composition includes a non~radi~

fate and gallium bromide.
20. A'radiopharmaceutical composition according to

oactive indium-transferrin complex.

24. A radiopharmaceutical composition, consisting
essentially of:

claim 1, wherein said composition includes a complex of
radioactive gallium and transferrin.

an effective tumor imaging . amount of radioactive

21. A radiopharmaceutical composition according to
claim 1, wherein said composition includes an organic

gallium, an effective tumor imaging improving
amount of non-radioactive indium; and.
a pharmaceutically acceptable carrier or diluent.

salt of non-radioactive indium selected from the group
consisting of indium citrate, indium lactate, indium tar

trate, indium phytate and indium phthallate.

10

' 22. A radiopharmaceuticall composition according to

sisting of gallium citrate, gallium lactate, gallium tar
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